NYSEMKT: CANFCan Fite Biopharma Ltd Stock
$1.20-0.03 (-2.44%)
Updated Apr 17, 2025
CANF Price
$1.20
Fair Value Price
N/A
Market Cap
$10.74M
52 Week Low
$1.18
52 Week High
$4.69
P/E
N/A
P/B
1.98x
P/S
17.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$674.00k
Earnings
-$7.88M
Gross Margin
100%
Operating Margin
-1,169.14%
Profit Margin
-1,169.1%
Debt to Equity
0.68
Operating Cash Flow
-$8M
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CANF Overview
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CANF's potential to beat the market
- CANF doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CANF
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CANF news, forecast changes, insider trades & much more!
CANF News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CANF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CANF is good value based on its book value relative to its share price (1.98x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
CANF's cash burn is expected to be positive in the next year ($2.99M), after accounting for decreasing cash burn (60.88%)
Interest Coverage Financials
CANF's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more CANF due diligence checks available for Premium users.
Valuation
CANF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-177.72x
Market
27.98x
CANF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.98x
Industry
4.05x
CANF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CANF's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CANF's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CANF's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.1M
Liabilities
$3.7M
Debt to equity
0.68
CANF's short-term assets ($8.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CANF's short-term assets ($8.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CANF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CANF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CANF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CANF vs Biotech Stocks
Can Fite Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.